Encorafenib is a targeted therapy medication used to treat melanoma (skin cancer) that has a specific genetic mutation called BRAF V600. It works by blocking the abnormal BRAF protein that helps cancer cells grow.

Binimetinib is also a targeted therapy medication that works together with Encorafenib. It blocks a different protein called MEK, which is also involved in cancer cell growth. When used together with Encorafenib, it helps to more effectively stop or slow down the growth of melanoma cells.

Radiotherapy is a treatment that uses high-energy radiation beams to target and destroy cancer cells, specifically used in this trial to treat large metastases (areas where cancer has spread).

Surgery involves the physical removal of metastatic tumors by surgical procedures.

Electrochemotherapy is a treatment that combines chemotherapy with electrical pulses to help the anti-cancer drugs enter cancer cells more effectively, making the treatment more powerful against metastases.

Melanoma – A type of skin cancer that develops from melanocytes, the cells that produce melanin pigment. It begins when normal melanocytes become transformed into cancer cells and grow uncontrollably, often starting as a new spot on the skin or from an existing mole that changes in appearance. In its advanced stages (unresectable or metastatic), the cancer cannot be completely removed by surgery or has spread to other parts of the body. When melanoma has a BRAF V600 mutation, it means the cancer cells have a specific change in their DNA that affects how they grow and divide. This form of melanoma can progress more aggressively than other types, spreading beyond its original location to other organs and tissues.